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Abstract
Background: This study aims to determine the maximum price at which HIV vaccination is cost-effective in the
Thai healthcare setting. It also aims to identify the relative importance of vaccine characteristics and risk behavior
changes among vaccine recipients to determine how they affect this cost-effectiveness.
Methods: A semi-Markov model was developed to estimate the costs and health outcomes of HIV prevention
programs combined with HIV vaccination in comparison to the existing HIV prevention programs without
vaccination. The estimation was based on a lifetime horizon period (99 years) and used the government
perspective. The analysis focused on both the general population and specific high-risk population groups. The
maximum price of cost-effective vaccination was defined by using threshold analysis; one-way and probabilistic
sensitivity analyses were performed. The study employed an expected value of perfect information (EVPI) analysis
to determine the relative importance of parameters and to prioritize future studies.
Results: The most expensive HIV vaccination which is cost-effective when given to the general population was
12,000 Thai baht (US$1 = 34 Thai baht in 2009). This vaccination came with 70% vaccine efficacy and lifetime
protection as long as risk behavior was unchanged post-vaccination. The vaccine would be considered cost-
ineffective at any price if it demonstrated low efficacy (30%) and if post-vaccination risk behavior increased by 10%
or more, especially among the high-risk population groups. The incremental cost-effectiveness ratios were the most
sensitive to change in post-vaccination risk behavior, followed by vaccine efficacy and duration of protection. The
EVPI indicated the need to quantify vaccine efficacy, changed post-vaccination risk behavior, and the costs of
vaccination programs.
Conclusions: The approach used in this study differentiated it from other economic evaluations and can be
applied for the economic evaluation of other health interventions not available in healthcare systems. This study is
important not only for researchers conducting future HIV vaccine research but also for policy decision makers who,
in the future, will consider vaccine adoption.
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HIV infection leading to AIDS has become the most
serious cause of disability adjusted life years lost in the
Thai population [1]. Thailand is often referred to as a
success story because of the fact that it has slowed
down the HIV epidemic through several effective mea-
sures, including public education campaigns, the preven-
tion of mother-to-child transmission (PMTCT) through
the use of antiretroviral drugs and formula feeding, a
100% condom use program among commercial sex
workers, etc. [2-5]. However, high HIV prevalence has
recently been observed among particular population
groups: men who have sex with men (MSM), injecting
drug users (IDUs), female sex workers (FSWs), and
migrant workers. In 2010, a total of 532,500 people
were living with HIV and 12,800 new infections were
reported in Thailand [6].
Because the above HIV prevention interventions
proved that they had only a limited effect on the
spread of HIV, the development of new preventive
tools remains important, especially for some hard-to-
reach population groups. Previous published economic
evaluations of HIV vaccination have been conducted in
many settings, including Thailand, and have shown
promising results in terms of restraining the spread of
the disease among the general population [7], women
[8], new-borns [9], and children aged up to 10 years
old [10]. A randomized clinical trial on the prime-
boost combination of HIV vaccination (ALVAC-HIV
®
and AIDVAX B/E
®)w a se s t a b l i s h e di nT h a i l a n dt o
evaluate the vaccination program’s efficacy among
16,402 members of the general population aged
between 18 and 30 years old [11]. The trial was con-
ducted by the Ministry of Public Health-Thai AIDS
Vaccine Evaluation Group (MOPH-TAVEG) under the
conditions of a prior agreement. If the vaccine shows
promising results and it can be registered in the Thai
market, the company will give special privileges to the
government to purchase the vaccine at a discounted
price.
As a result, prior to the announcement of the trial
results in September 2009, this economic evaluation was
conducted at the request of policy makers aiming to
determine policy decisions regarding the adoption and
price negotiation of the vaccine. This study aims to
determine the maximum price at which the vaccine
remains cost-effective in the Thai healthcare setting. It
also aims to identify the relative importance of vaccine
characteristics, i.e. cost of vaccination, vaccine efficacy,
duration of protection, and vaccine acceptance rates, as
well as risk behaviors that have changed post-vaccina-
tion, all of which may affect the vaccine’sc o s t -
effectiveness.
Methods
Study design
This is a model-based economic evaluation for which a
semi-Markov model (Figure 1) was developed using
Microsoft excel
® (Microsoft Corp., Redmond, WA) in
order to estimate the incremental cost-effectiveness
ratio (ICER) in terms of cost per quality-adjusted life
year (QALY). The HIV vaccination combined with the
existing HIV prevention programs was compared to the
existing HIV prevention programs without HIV vaccina-
tion. The assessment was made from a government
perspective.
The existing HIV prevention programs include 1) a
condom use program, which provides free condoms in
readily visible and accessible sites through healthcare
facilities and private businesses serving population
groups at high risk of sexually transmitted diseases
(STDs) and HIV; 2) school-based education, which pro-
vides information to young people and reinforces healthy
norms in a school setting; 3) anti-retroviral prophylaxis
for vertical HIV transmission, which delivers free volun-
tary HIV counseling and testing (VCT) services for all
pregnant women, as well as providing HIV infected preg-
nant women with free antiretroviral treatment (ART),
breast milk substitutes for 12 months, and counseling
with their partner to test their newborn babies at 12 and
18 months and recruit them into universal ART pro-
grams when CD4 counts indicate the necessity; 4) diag-
nosis and treatment of sexually transmitted infections; 5)
an e e d l ea n ds y r i n g ep r o g r a m ,w h i c ho f f e r st h eo p p o r t u -
nity for IDUs who continue injecting to safely dispose of
used needles and syringes and to obtain clean drug injec-
tion equipment at no cost; and 6) screening blood pro-
ducts and donated organs for HIV.
The analysis focused on particular target population
groups: the general population aged 18 to 30 years old,
FSW, IDU, MSM, and military conscripts. As mentioned
already, at the time this study was conducted, there was
no HIV vaccine available in the market, nor did the
results of the HIV vaccine efficacy trial in Thailand
reveal anything conclusive [11]. A number of assump-
tions relating to population behavior patterns and vac-
cine characteristics have been put forward as follows:
(1) Vaccine efficacy: A figure of 50% vaccine efficacy
was applied for the base-case scenario, and a range of
30%-70% was used in the uncertainty analysis.
(2) Duration of protection: It was assumed in the
base-case scenario that the vaccine’s effects last for 10
years; however, both longer and shorter time periods of
vaccine protection were used in the uncertainty analysis.
(3) Vaccine cost: The base case analysis applies a vac-
cine cost of 3,500 Thai baht (THB), or approximately
US$100 (US$1=34 THB in 2009), as recommended by
Leelahavarong et al. BMC Public Health 2011, 11:534
http://www.biomedcentral.com/1471-2458/11/534
Page 2 of 15the International AIDS Vaccine Initiative [12] for a full
course of immunization (6 doses each of prime and
boost injections). The study varies significantly regarding
the vaccine cost when examining the maximum level at
which the vaccine still offers viable cost-effectiveness
[12,13].
(4) Vaccine acceptance rates: Research by Suraratde-
cha et al. [14] reported that nearly 80% of adults would
accept HIV vaccination if it were free of charge. There-
fore, the base-case scenario adopts an 80% acceptance
rate, while a range of 30% to 100% was applied in the
uncertainty analysis.
(5) Change in risk behaviors as a result of receiving
the vaccine: This study assumed change of risk beha-
viors in terms of the decreasing rate of condom use for
all target population groups and an increasing rate of
needle sharing for IDUs from 0% (unchanged) to 30%
(significant change) [15,16].
In addition, the model was run to predict relevant
costs and outcomes over a 99-year period (lifetime hori-
zon). Both future costs and outcomes were discounted
at the rate of 3% per annum as suggested by the Thai
economic evaluation guideline [17].
Epidemiological data
Baseline HIV incidence
The age-specific incidences of HIV infection among the
general population in Thailand were used to estimate
the probability of moving from a HIV negative state to
an HIV asymptomatic state (early HIV positive) [18].
For four high-risk population groups, statistics for the
annual incidences of HIV infection were obtained from
the Sentinel Sero-Surveillance survey conducted at the
national level by the Bureau of Epidemiology, the Minis-
try of Public Health (MoPH), and some cohort studies
[19-21]. In addition, the average duration that FSWs,
IDUs, MSM, and male military conscripts remain at
high-risk is 4, 10, 20, and 2 years, respectively [6]. It was
presumed that after these periods, high-risk groups
would change their behavior, and that the annual prob-
ability of contracting HIV would then be similar to that
of the general population.
HIV/AIDS progression
The annual probabilities of progressing from being HIV
asymptomatic to HIV symptomatic among Thai people
living with HIV/AIDS was identified from published lit-
erature [22]. The progression from an HIV symptomatic
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Figure 1 As e m i - M a r k o vm o d e l . The provision of HIV vaccination was on a voluntary basis, so the target population had the option of
accepting or refusing the vaccine. The model consists of five health states: (1) HIV negative; (2) HIV positive without symptoms (asymptomatic);
(3) progression into HIV with related symptoms (symptomatic); (4) AIDS state during antiretroviral treatment (ART), which includes three sub
states, i.e., the first-line ART, the second-line ART, and the third-line ART regimens; and (5) death due to HIV infection and other causes. The
arrows represent the probability of transitions from one state to another.
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between the number of new AIDS patients at the end of
2008 and the number of people living with HIV in that
year [6,10]. The AIDS patients in this study were
assumed to have started the first-line ART regimen and
then switched to the second-line regimen and onto the
third-line regimen. It was noted that the third stage may
cause patients to develop severe adverse effects, drug
resistance, or major opportunistic infections. This infor-
mation was obtained from an HIV cohort consisting of
646 patients receiving ART [23].
The annual mortality rates among HIV asymptomatic,
HIV symptomatic and AIDS patients were estimated
from two cohort studies in Thailand. The two cohorts
were made up of 880 HIV/AIDS patients [23,24]. The
age-adjusted annual probability of dying from other
causes was derived from the Burden of Disease and
Injury Study in Thailand [1]. The epidemiological data
derived from the model, i.e. the survival of HIV patients
compared to the general population and the average
duration of each health state (Figure 2), were finally
approved by Thai HIV experts in a meeting held on 18
September, 2009.
Change in risk behaviors
This analysis also assumed an increase in risk behavior
among those vaccinated, i.e. decreased condom use
among the general population, FSWs, MSM, and male
military conscripts, as well as increased needle sharing
among IDUs. It is expected that the increased risk beha-
vior would range from slight (10%) to significant (30%).
The impact of risk behavioral changes post-vaccination
was estimated by using a dynamic model: the “Asian
Epidemic Model (AEM)” (Wiwat Peerapatanapokin,
East-West Center, Hawaii, U.S.A./Policy Research
Development Institute Foundation (PRI), personal com-
munication, September 29, 2009). The AEM is a simula-
tion model that simulates behavior, dynamics linkages,
and interaction among subpopulations. It has been offi-
cially used for HIV/AIDS projection in Thailand since
the year 2000 [6].
Costs data
All costs were converted into and reported in 2009 THB
rates [25]. For international comparison, costs were con-
verted into international dollars using a purchasing
power parity (PPP) exchange rate (a PPP 2009 dollar =
16.55 THB) [26]. Based on the government perspective,
only direct medical costs were included. The National
AIDS Spending Assessment in Thailand reported the
total national expenditure on HIV prevention; the fig-
ures for the target population were derived from the
Department of Local Administration, while the Ministry
of the Interior predicted the cost of HIV prevention per
target person [27,28].
The costs associated with HIV vaccination included
vaccine costs (i.e. price per dose, delivery costs, and sto-
rage costs), costs of community engagement, and costs
of pre- and post-HIV vaccination counseling. Also, the
study assumed that each booster revaccination required
a full course and that revaccination was needed in order
to gain effective protection over a 30-year time period,
which was thought to cover the period when people are
at high risk of infection. Community engagement is
needed to raise awareness of the vaccine among the tar-
get population, and this would also help to obtain a
high vaccine acceptance rate. The cost of 937 THB per
individual form the target population was estimated in a
vaccine clinical study in Thailand (Nakorn Premsri,
National Vaccine Committee Office, Department of Dis-
ease Control, MoPH, personal communication, August
25, 2009).
The annual direct medical costs of HIV/AIDS treat-
ment, including the costs of ART, were obtained from
the National Health Security Office (NHSO). The costs
of the three ART regimens were derived from the
National database (Thanapat Laowahutanon, AIDS
office, Bureau of Disease Management, NHSO, personal
communication, August 20, 2009) and adjusted to
match the proportion of utilization among patients,
which changes over time as a result of ART resistance.
The costs of laboratory testing, follow-up treatment, and
treatment of opportunistic infections were derived from
a study entitled “The economics of effective AIDS treat-
ment study in Thailand” [29].
Health outcome variables
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Figure 2 Model validation. (A) The survival curve of HIV patients
compared to the general population (B) The estimated life years
since infection classified by risk group MSM: men who have sex
with men; IDU: injecting drug user; and FSW: female sex worker
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and 1 = full health) for calculating QALY were obtained
from Leelukkanaveera’s study [24], which collected the
quality of life data of 1,277 HIV infected patients in 16
community hospitals in Thailand using the EQ-5D
instrument. The HIV/AIDS patients’ quality of life was
classified by disease stage, i.e. asymptomatic HIV, symp-
tomatic HIV, and AIDS, to be 0.86, 0.80, and 0.76,
respectively.
Uncertainty analysis
One-way sensitivity analysis was performed to examine
the relative importance of the four parameters assumed.
These are vaccine efficacy, duration of vaccine protec-
tion, vaccine acceptance rate, and change in risk beha-
vior. Only significant parameters identified from one-
way sensitivity analysis were used in the threshold analy-
sis to quantify the maximum costs of the vaccine to the
given ceiling threshold of 100,000 THB per QALY
gained [30]. Based on the statement of the Subcommit-
tee for the Development of the National List of Essential
Drugs and the Subcommittee for the Development of
the Health Benefit Package and Service Delivery of the
NHSO in 2007, the societal willingness to pay (WTP)
threshold for a QALY gained for the adoption of health
interventions is 100,000 THB (6,000 PPP$), approximat-
ing per capita Gross Domestic Product (GDP) [30]. This
value is in accordance with the recent community sur-
vey aimed at identifying households’ willingness-to-pay
for a QALY, the detailed approach of which will be pub-
lished elsewhere [31].
In addition, probabilistic sensitivity analysis (PSA) was
conducted to assess uncertainty surrounding all model
parameters given the mean, standard error (SE), and
distribution of each parameter as shown in Table 1, 2
and 3. Probability distributions were defined as follows
[32]: (1) beta-distributions were assigned where para-
meter values ranged from zero to one, such as transition
probabilities and utility parameters; (2) gamma-distribu-
tions were specified when parameter values were above
zero and positively skewed by costs variables; and (3) a
log-normal distribution was used for survival para-
meters. The PSA was conducted by using a second
order Monte Carlo simulation performed by Microsoft
excel
® (Microsoft Corp., Redmond, WA) and run for
1,000 iterations to yield a range of plausible values for
lifetime costs, quality-adjusted life years (QALYs), and
incremental cost-effectiveness ratios (ICERs) [33]. The
results were depicted in graphs that plotted the prob-
ability of HIV vaccination being cost-effective against
different vaccine costs.
The study also performed a value of information ana-
lysis to determine the population expected value of per-
fect information (EVPI) and the partial EVPI to
determine whether different values of a particular input
parameter lead to different optimum decisions
[11,34-36] (see Appendix) and if so, how much the
expected loss under alternative optimum decisions var-
ies given the scenario that the vaccine efficacy is 31.2%
(95% confidence interval-CI, 1.1 to 51.2) as revealed in a
recent vaccine trial in Thailand [11]. The vaccine cost
was fixed at 210 THB with an 80% vaccine acceptance
rate and a 10-year vaccine protection duration. Because
the analysis of partial EVPI requires an explicit state-
ment of the value of the ceiling ratio, this analysis
applied the Thai WTP threshold at 100,000 THB [30].
Results
Cost-utility analysis
The results shown in Table 4 are average lifetime costs
and the QALYs of an HIV vaccination program com-
pared to existing prevention programs. The results are
classified by risk group. The study found that for the
general population, the vaccine was most cost-effective
for 18 year olds with an ICER of approximately 157,000
THB per QALY. For high risk population groups, the
vaccine was very cost-effective for IDUs and MSM due
to higher effectiveness and lower costs compared with
existing prevention programs. For other high risk
groups, the vaccine was cost-ineffective.
Uncertainty analysis
One-way sensitivity analysis
A tornado diagram shown in Figure 3 illustrates the
results of one-way sensitivity analysis, and indicates that
the ICER per QALY gained was most sensitive to
changes in risk behavior post-vaccination from 0% to
30%. This was followed by vaccine efficacy of between
30% and 70%, and the duration of protection in a range
of from 5 years to a lifetime period, while the altering of
acceptance to vaccination ranges between 30% and
100% had the least influence on the changing of the
ICER.
Using the one-way sensitivity results, only the signifi-
cant parameters (i.e. risk behavior change, vaccine effi-
cacy, and duration of protection) were used to identify
the maximum costs of the vaccine shown in Table 5.
The highest costs of the vaccine that is still cost-effec-
tive under the Thai healthcare setting was for the sce-
nario where the vaccine has 70% efficacy with lifetime
protection; no changes occur in risk behavior post-vacci-
nation; and the vaccine is provided to MSMs. Overall,
the vaccine has the best cost-effectiveness when being
provided to MSMs, followed by IDUs, FSWs, the general
population aged 18 years old, male military conscripts,
and the general population aged 30 years old.
In contrast, in certain cases it has been found that
p r o v i d i n gt h ev a c c i n ef r e eo fc h a r g et os o m ep a r t i c u l a r
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prevention programs. These cases are:
(1) where the vaccine has a range of 30% to 70% effi-
cacy with 5-year and 10-year protection, and 30% effi-
cacy with lifetime protection provided for the general
population aged 30 years old.
(2) where the vaccine has 30% efficacy with 5-year
protection, and no changed risk behavior post-vaccina-
tion provided for the general population aged 18-30
years old and male military conscripts.
(3) where the vaccine has 30% efficacy with all dura-
tions of protection, and changed risk behavior post-vac-
cination of 10% provided for FSWs and MSMs, and
changed risk behavior post-vaccination of 20% for the
general population aged 18 years old, and IDUs.
(4) where the vaccine has 50% efficacy with all dura-
tions of protection, and changed risk behavior post-vac-
cination of 20% provided for the general population
aged 18 years old, FSWs, and MSMs.
Probabilistic sensitivity analysis
Figure 4 illustrates the results of PSA in the form of
graphs showing probabilities of different vaccine costs
and the duration of protection being cost-effective at
the Thai WTP threshold of 100,000 THB per QALY
gained. The results show that when the efficacy is at
30% (Figure 4A), 50% (Figure 4B), and 70% (Figure 4C)
with lifetime protection, the maximum cost could be
defined as 4,000 THB, 7,000 THB, and 10,000 THB,
respectively, with the probabilities of being cost-effective
set at 60%, 62%, and 65%, respectively. For 10-year
Table 1 Input parameters (i.e. discount rate and transition probabilities) used in Markov model
Parameters Distribution Mean SE References
Yearly discount rate (%)
Costs (range) 3 (0-6) [17]
Outcome (range) 3 (0-6) [17]
Transition probabilities
Probabilities of HIV infection classified by risk group
Annual incidences of HIV infected in general population aged 18 years Beta 0.001 [18]
Annual incidences of HIV infection in FSW Beta 0.022 0.016 [19]
Annual incidences of HIV infection in IDU Beta 0.034 0.002 [20]
Annual incidences of HIV infection in MSM Beta 0.055 0.010 [21]
Annual incidences of HIV infection in male conscripts Beta 0.002 0.001 [19]
Transition probabilities of HIV positive with asymptomatic state
Annual progression risk from asymptomatic to symptomatic state Beta 0.865 0.047 [46]
Annual death risk of asymptomatic state Beta 0.058 0.008 [22]
Transition probabilities of HIV positive with symptomatic state
Annual probability to progress from HIV to AIDS Beta 0.087 0.0004 [6,10]
Constant in survival analysis for baseline hazard Lognormal -8.38 1.44 [24]
CD4 coefficient in survival analysis for baseline hazard Lognormal -0.01 0.001 [24]
Ancillary parameter in Weibull distribution Lognormal 0.04 0.19 [24]
Average CD4 of patients (#patients=234) Lognormal 321.44 9.46 [24]
Transition probabilities of AIDS state to death
Constant in survival analysis for baseline hazard Lognormal -4.81 0.86 [23]
Age coefficient in survival analysis for baseline hazard Lognormal -0.04 0.02 [23]
CD4 coefficient in survival analysis for baseline hazard Lognormal -0.02 0.00 [23]
Ancillary parameter in Weibull distribution Lognormal -0.33 0.11 [23]
Average CD4 of patients (#patients=646) Gamma 81.01 2.67 [23]
Transition probability of switching from first-line to second-line ART regimen
Constant in survival analysis for baseline hazard Lognormal -6.17 0.52 [23]
CD4base coefficient in survival analysis for baseline hazard Lognormal 0.003 0.001 [23]
Age coefficient in survival analysis for baseline hazard Lognormal 0.0313 0.0113 [23]
Ancillary parameter in Weibull distribution Lognormal -0.49 0.07 [23]
Transition probability of switching from second-line to third-line ART regimen
Constant in survival analysis for baseline hazard Lognormal -10.29 1.27 [23]
Age coefficient in survival analysis for baseline hazard Lognormal 0.06 0.02 [23]
Ancillary parameter in Weibull distribution Lognormal 0.01 0.14 [23]
SE: standard error; FSW: female sex worker; IDU: injecting drug user; and MSM: men who have sex with men.
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Parameters Distribution Mean SE References
Costs of prevention program
Annual costs of existing prevention programs Gamma 24 [27,28]
Cost of HIV vaccine per course Gamma 3,500 [12]
Individual cost of community engagement Gamma 937*
Cost of HIV screening (ELISA) for vaccine acceptance Gamma 125 [47]
Cost of pre-counselling for all vaccinations Gamma 141 [47]
Cost of post-counselling for vaccine acceptance Gamma 58 [47]
Costs of treatment program
Costs of asymptomatic treatment
Laboratory cost for asymptomatic patient Gamma 8,155 [29]
Hospital service cost of asymptomatic patient Gamma 2,502 [29]
OPD cost of asymptomatic patient Gamma 2,502 [29]
Costs of symptomatic treatment
Lab test cost for symptomatic patient Gamma 8,931 [29]
Opportunity infection treatment cost of symptomatic patient Gamma 4,739 [29]
Hospital service cost of symptomatic patient Gamma 9,104 [29]
OPD cost of symptomatic patient Gamma 2,502 [29]
IPD cost of symptomatic patient Gamma 6,227 [29]
Costs of AIDS treatment
Opportunity infection treatment cost of AIDS patient Gamma 4,739 [29]
Hospital service cost of AIDS patient Gamma 9,104 [29]
OPD cost of AIDS patient Gamma 2,502 [29]
IPD cost of AIDS patient Gamma 6,227 [29]
Annual drug costs of the first-line ART regimens (mg): Gamma 8,184
† 1,858
†
1. d4T(30)+3TC(150)+NVP(200) or
2. d4T(30) + 3TC(150) + EFV (600) or
3. AZT(100/200/250/300)+3TC(150)+NVP(200) or
4. AZT(100/200/300)+3TC(150)+EFV(600)
Annual drug costs of the second-line ART regimens (mg): Gamma 32,478
† 5,772
†
1. ddI(250)+3TC(150)+NVP(200) or
2. ddI(250)+3TC(150)+EFV(600) or
3. TDF(300)+3TC(150)+NVP(200) or
4. TDF(300)+3TC(150/300)+EFV(600)
Annual drug costs of the third-line ART regimens (mg): Gamma 15,682
† 2,080
†
1. AZT(100/200/300)+3TC(150)+Boosted PIs
‡ or
2. d4T(30)+3TC(150)+Boosted PIs
‡ or
3. TDF(300)+3TC(150)+Boosted PIs
‡ or
4. ddI(250)+3TC(150)+Boosted PIs
‡ or
5. AZT(100/200/300)+ddI(250)+Boosted PIs
‡ or
6. AZT(100/200/300)+TDF(300)+Boosted PIs
‡ or
7. AZT(100/200/300)+3TC(150)+TDF(300)+Boosted PIs
‡
Annual costs of lab test of first-line ART regimen in the first year Gamma 7,671 [48]
Annual costs of lab test of first-line ART regimen in subsequence years Gamma 4,210 [48]
Annual costs of lab test of the second-line ART regimen Gamma 4,140 [48]
Annual costs of lab test of the third-line ART regimen Gamma 4,163 [48]
SE: standard error; THB: Thai baht; OPD: outpatient department; IPD: inpatient department; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP:
nevirapine; EFV: efavarenze; AZT; zidovudine; TDF: tenofovir; ddI: dianosine; and PIs: protease inhibitors.
*Nakorn Premsri, National Vaccine Committee Office, Department of Disease Control, Ministry of Public Health, personal communication, August 25, 2009.
†Thanapat Laowahutanon, AIDS office, Bureau of Disease Management, National Health Security Office, personal communication, August 20, 2009.
‡Boosted PIs were recommended by National Health Security Office as follows: the first-line PIs regimen, LPV/r– lopinavir (200 mg) + ritonavir(50 mg) or IDV/r–
indinavir (400 mg) + ritonavir (100 mg) and the second-line PIs regimen, ATV/r– atazanavir (150 mg)+ ritonavir (100 mg)
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Page 7 of 15protection, the costs of vaccine efficacy of 30%, 50%, and
70% would be decreased to 1,000 THB, 2,000 THB, and
4,000 THB, respectively, with the probabilities of being
cost-effective standing at 60%, 70%, and 58%, respec-
tively. HIV vaccination with a 5-year duration of protec-
tion with 30% and 50% efficacy might not be cost-
effective, while with 70% efficacy combined with a vac-
cine cost of 1,000 THB would provide a probability of
cost-effectiveness of 72%.
Value of information analysis
Figure 5A presents the population EVPI, i.e. the
expected loss due to making a wrong decision at differ-
ent ceiling ratios as a result of uncertainty in the overall
parameters used in the model. The population EVPI for
a 5-year period was analyzed in a hypothetical situation
with the provision of a HIV vaccination program for the
general population aged 18 years old with the hypotheti-
cal characteristics of the vaccine as follows: (1) an effi-
cacy of 31.2% based on prime-boost efficacy trials, (2) a
vaccine cost of 210 THB based on threshold analysis,
(3) an acceptance of vaccination rate of 80%, and (4) 10-
year protection and 3 boosters with full courses. The
EVPI was highest at a ceiling ratio of 100,000 THB per
QALY gained to be 5,400 million THB.
Since the results of population EVPI found the maxi-
mum value of the ceiling ratio to be at 100,000 THB, this
ratio was taken for the partial EVPI analysis to examine
the relative importance of each parameter used in the
model. The results shown in Figure 5B present the esti-
mated cost and the priority of further research to ascer-
tain the perfect information of each parameter. The most
important input parameters were vaccine efficacy and
post-vaccination changes to risk behavior. The estimated
value of partial EVPI of these 2 parameters stood at 1,900
million THB and 1,500 million THB, respectively. This
was followed by the costs of the HIV vaccination pro-
gram including community engagement, counselling, and
screening for HIV infection where the total estimated
partial EVPI was 570 million THB. The least important
parameters were the probabilities of HIV infection, dis-
ease progression, the costs of HIV/AIDS treatment, and
the utilities value of each HIV/AIDS state.
Table 3 Input parameters (i.e. utility parameters and characteristics of HIV vaccine) used in Markov model
Parameters Distribution Mean SE References
Utility parameters
Utility of HIV negative 1
Utility of asymptomatic patients Beta 0.86 0.01 [24]
Utility of symptomatic patients Beta 0.80 0.01 [24]
Utility of AIDS patients Beta 0.76 0.01 [24]
Characteristics of HIV vaccine
Vaccine efficacy Gamma 31% 13% [11]
Increased incidences of HIV infection compared to baseline due to the change of risk behaviors Gamma 20%* 20%*
Duration of booster doses (year) Gamma 10* 10*
SE: standard error.
*Based on assumption
Table 4 Incremental cost-effectiveness ratios (ICERs) of HIV vaccination program compared to existing prevention
program, classified by risk group
HIV vaccination program Existing prevention programs ICER
Costs (THB) QALY Costs (THB) QALY THB per QALY gained*
General population
aged 18 years old 12,900 25.73 5,490 25.68 157,000
FSW
aged 29 years old 47,300 23.46 46,800 23.25 2,840
IDU
aged 26 years old 53,900 13.03 62,400 12.61 Dominated
†
MSM
aged 26 years old 243,000 16.51 245,000 16.27 Dominated
†
Male conscript
aged 21 years old 11,400 23.80 4,570 23.78 326,000
ICER: incremental cost-effectiveness ratio; FSW: female sex worker; IDU: injecting drug user; MSM: men who have sex with men; THB: Thai baht as of 2009 value;
and QALY: quality adjusted life year.
*ICERs are rounded up to nearest 1,000 THB.
†Negative ICER due to higher effectiveness and lower costs of HIV vaccination program compared with existing prevention programs.
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This is the first cost-utility study comparing a combina-
tion of HIV vaccination and existing HIV prevention
programs with existing HIV prevention programs with-
out HIV vaccination in both the general population and
high-risk population groups. This study shows that pro-
viding a HIV vaccine is more cost-effective for high-risk
groups than for the general population if the vaccine
recipients do not change their risk behaviour post-vacci-
nation. The changing of risk behavior after vaccination
is one of the major parameters influencing the effective-
ness and cost-utility of the vaccine, followed by vaccine
efficacy, and the duration of protection. Therefore,
adoption of the HIV vaccine with partial protection
(30%-70%) into the healthcare system should be ser-
iously considered alongside the potential change of risk
behavior among the vaccinated population. In future
clinical trials of the HIV vaccine these parameters need
to be closely monitored. This study also helps inform
decision makers of the maximum costs of HIV vaccina-
tion at which the vaccine would likely be cost-effective
considering the Thai ceiling threshold of 100,000 THB
per QALY gained [30].
Two economic evaluations previously published in
international journals were identified [9,10]. One focuses
on the use of a HIV vaccine with 30% efficacy in infants
in Sub-Saharan Africa, while the other considers a HIV
vaccine with 60% efficacy for 10-year-old children in
Thailand. Both studies reveal that the HIV vaccine is
cost-effective compared to non vaccination. Similarly to
the results of this study, these two published papers also
indicate that the cost-utility of a HIV vaccine depends
very much on baseline HIV incidences and vaccine effi-
cacy, although they did not consider the change of risk
behavior. It is interesting to note that the results of
these two papers did not favor the vaccine as much as
the findings of this study because the major benefit of
childhood HIV vaccination would not be observed until
twenty-five years in the future.
Thailand experienced the use of economic evaluation
for decision making regarding the adoption of new HIV
prevention interventions. Thef i r s tr e l a t e st ot h eu s eo f
ART for the prevention of vertical HIV transmission or
PMTCT [37,38]. In 2004, economic evidence supported
the use of a combination of zidovudine (AZT) + nevira-
pine (NVP), and in 2010, the national policy was chan-
ged again when the economic analysis supported the
use of a combination of AZT+ lamivudine (3TC) + lopi-
navir/ritonavir (LPV/r). The second policy change
included the introduction of provider-initiated HIV
counseling and testing instead of voluntary HIV coun-
seling and testing. All of these interventions demon-
strated that they yield a QALY at a cost that is below
the Thai ceiling threshold [39]. This study is in line with
the results from a household survey in Thailand which
found that, when having sexual relations with partners
who are not spouses, condom use among the HIV vacci-
nated was likely to be lower than among those not vac-
cinated [14]. Similarly, Newman et al. [40] reported the
intentions of increasing post-vaccination risk behavior,
including decreased condom use and an increased num-
ber of partners among the MSM population in Thailand
if they were vaccinated with the HIV vaccine. Two stu-
dies [15,16] constructed epidemiological models and
predicted that the introduction of a low efficacious HIV
vaccine could worsen the HIV epidemic if increased risk
behavior after vaccination was observed. As a result,
introduction of the vaccine needs to be combined with
other effective measures to prevent and monitor risk
behaviors that may be changed post-vaccination, espe-
cially for a vaccine with only partial efficacy.
The findings of this study should be considered care-
fully. Firstly, this study did not account for the potential
benefits of prolonged disease progression among vacci-
nated population groups who were subsequently
infected by the virus [10]. However, the recent HIV vac-
cine trial in Thailand reported no difference in terms of
viral load and CD4+ T-cell counts between vaccinated
and non-vaccinated groups [11]. Secondly, although this
study assumed a very high acceptance rate of HIV vacci-
nation (80%), the model did not take into account the
potential benefit of herd immunity. This could lead to
Figure 3 One-way sensitivity analysis. The diagram shows the
sensitivity of ICER to hypothesis ranges of characteristics of the HIV
vaccine. The numbers at each end of the bars indicate the most
extreme values used in the sensitivity analysis. ICER: incremental
cost-effectiveness ratio; THB: Thai baht as of 2009 value; and QALY:
quality adjusted life year. *Percentage of risk behavior changes (0%-
30%) due to vaccination (i.e. decreasing condom usage and
increasing habit of needle sharing among injecting drug users) †
The study assumed that each boosted revaccination required a full
course and the revaccination was needed to maintain protection
over a 30-year period.
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Page 9 of 15an underestimation of the efficacy and cost-effectiveness
of the vaccine. Thirdly, since the vaccine is not available
in the market, the assumptions of vaccine characteristics
needs to be derived from expert consultations in order
to define the possible range of those parameters. How-
ever, this study extensively explored parameter uncer-
tainty and provided valuable information using a new
approach - EVPI analysis - to prioritize model para-
meters for future fine tuning. Fourthly, even though the
societal perspective is recommended in the current
Health Technology Assessment Guidelines in Thailand
[41], this study adopted a government perspective in the
analysis. This is because the direct medical care costs
are likely to be a major cost component. A future study
should be conducted using the societal viewpoint in
which the increased economic productivity of indivi-
duals whose infection has been averted is counted. This
w o u l dm a k et h ev a c c i n em o r ep r e f e r a b l ea se m p i r i c a l
evidence indicated that HIV/AIDS significantly affected
household economies [42]. Fifthly, this study did not
consider other factors that are relevant to policy deci-
sions regarding health resource allocation in Thailand.
These include affordability, equity and politics, as well
as social and cultural dimensions [43-45]. Finally,
Table 5 The results of threshold analysis present the HIV vaccine prices being cost-effective, classified by risk group
Vaccine prices (THB) being cost-effective at a WTP threshold 100,000 THB per QALY gained
Duration of protection Lifetime 10 years 3 boosters with full
course
†
5 years 6 boosters with full
course
†
Vaccine efficacy 30% 50% 70% 30% 50% 70% 30% 50% 70%
Risk behavior changed*
General population aged 18 years old
Unchanged 4,400 7,900 12,000 1,100 2,700 4,300 - 730 1,600
Increased 10% 2,400 6,500 11,000 210 2,000 3,900 - 380 1,400
Increased 20% - 4,500 9,600 - 1,100 3,400 - - 1,100
Increased 30% - 2,000 8,100 - 23 2,700 - - 760
General population aged 30 years old
Unchanged - 410 1,100 - - - - - -
Increased 10% - 180 960 - - - - - -
Increased 20% - - 780 - - - - - -
Increased 30% - - 550 - - - - - -
FSW aged 29 years old
Unchanged 52,000 85,000 120,000 23,000 38,000 54,000 12,000 20,000 29,000
Increased 10% - 37,000 92,000 - 16,000 41,000 - 8,000 22,000
Increased 20% - - 59,000 - - 26,000 - - 14,000
Increased 30% - - 22,000 - - 9,500 - - 4,500
IDU aged 26 years old
Unchanged 57,000 96,000 140,000 35,000 58,000 82,000 21,000 34,000 48,000
Increased 10% 22,000 69,000 120,000 14,000 42,000 73,000 7,600 25,000 43,000
Increased 20% - 45,000 110,000 - 28,000 64,000 - 16,000 38,000
Increased 30% - 24,000 93,000 - 15,000 56,000 - 8,400 33,000
MSM aged 26 years old
Unchanged 170,000 310,000 500,000 100,000 170,000 250,000 59,000 98,000 140,000
Increased 10% - 40,000 260,000 - 24,000 140,000 - 14,000 82,000
Increased 20% - - 31,000 - - 19,000 - - 11,000
Increased 30% - - - - - - - - -
Military male conscript aged 21 years old
Unchanged 2,200 5,500 8,900 150 1,600 3,100 - 160 1,000
Increased 10% - 3,100 7,500 - 560 2,500 - - 650
Increased 20% - 320 5,800 - - 1,800 - - 240
Increased 30% - - 3,800 - - 850 - - -
THB: Thai baht as of 2009 value; WTP: willingness to pay; QALY: quality adjusted life year; FSW: female sex worker; IDU: injecting drug user; MSM: men who have
sex with men.
“-” HIV vaccine would not be cost-effective.
*Risk behavior changed due to vaccination (i.e. decrease in condom use and increase in needle sharing among injecting drug users)
†The study assumed that each boosted revaccination required a full course and the revaccination was needed to maintain protection over a 30-year period.
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Figure 4 Probabilistic sensitivity analysis. For probabilistic sensitivity analysis in the base case (i.e., general population aged 18 years old,
acceptance rate of 80%, and unchanged risk behaviors), these graphs demonstrate the probabilities of the HIV vaccine cost for each duration of
protection and each vaccine efficacy level of (A) 30%, (B) 50%, and (C) 70% being cost-effective at the WTP threshold of 100,000 THB per QALY
gained. ICER: incremental cost-effectiveness ratio; THB: Thai baht as of 2009 value; and QALY: quality adjusted life year.
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Figure 5 Expected value of perfect information. (A) Expected value of perfect population information for a model using the input parameters
of general population aged 18 years, and using characteristics of vaccine hypothesis as follows: 31.2% of vaccine efficacy, 210 THB vaccine costs,
80% acceptance rate, 10-year protection, and 3 boosters with full courses. THB: Thai baht as of 2009 value. (B) Partial expected value of perfect
information of parameters used in the model at a ceiling ratio of 100,000 THB per QALY gained for the provision of a HIV vaccination program
for the general population aged 18 years and using characteristics of vaccine hypothesis as follows: 31.2% vaccine efficacy, 210 THB vaccine
costs, 80% acceptance rate, 10-year protection, and 3 boosters with full courses. THB: Thai baht as of 2009 value; QALY: quality adjusted life year;
pHIVneg_HIVpos_Base: the probability of HIV infection among the general population; pAsym_Sym: the probability of transition from HIV
infection with asymptomatic state to a symptomatic state; pAsym_Death: the probability of transition from HIV infection with asymptomatic
state to death; pSym_AIDS: the probability of transition from HIV infection with symptomatic state to AIDS state; HzFnSymp_death: the
probability of death from HIV infection with symptomatic state analyzed from parametric survival analysis; HzFnAIDS_death: the probability of
death during AIDS state analyzed from parametric survival analysis; HzFnReg1_Reg2: the probability of switching ART first regimens to second
regimens among AIDS patients analyzed from parametric survival analysis; HzFnReg2_Reg3: the probability of switching ART second regimens to
third regimens among AIDS patients analyzed from parametric survival analysis; C_ComEn: individual cost of community engagement; C_Screen:
HIV screening cost; C_PreCou: cost of pre-counseling; TC_Asymp: total treatment cost of HIV infection in asymptomatic state; TC_Sym; total
treatment cost of HIV infection in symptomatic state; TC_NewAIDS: total treatment cost of new AIDS patient; TC_AIDS_Reg1: total cost of
treatment with the first ART regimens of AIDS patient; TC_AIDS_Reg2: total cost of treatment with the second ART regimens of AIDS patient;
TC_AIDS_Reg3: total cost of treatment with the third ART regimens of AIDS patient; TC_AIDS: total cost of other treatment of AIDS patient;
Uasym: utility weight of HIV infection with asymptomatic patient; Usym: utility weight of HIV infection with symptomatic patient; UAIDS utility
weight of AIDS patient; Risk: percentage of change in the risk behavior post-vaccination; Boost: the duration of vaccine protection; and Vac_eff:
vaccine efficacy
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Page 12 of 15although this study offers a useful and comprehensive
framework for evaluating the cost-effectiveness of HIV
vaccination, all input parameters used in the analysis are
mostly relevant to the Thai context and only a govern-
ment perspective was used; therefore, applying these
findings elsewhere should be done with caution.
Conclusions
Because a HIV vaccine is not yet available in the market,
this study was conducted using several assumptions
including vaccine efficacy, duration of protection, and
the change of risk behavior after vaccination. These
assumptions were made with the careful consideration
and involvement of various partners. This was to help
with transparency, to encourage participation, and to
help with the acceptance of this research. This approach
differentiated this study from other economic evalua-
tions and can be applied for the economic evaluation of
other health interventions not available in healthcare
systems. This kind of study can be very useful and
important not only for researchers conducting future
HIV vaccine research but also for policy decision
makers who, in the future, will consider vaccine adop-
tion in Thailand.
Appendix
Expected value of perfect information
The overall expected value of perfect information (EVPI)
is the difference between the expected net benefit of the
optimal strategy given perfect information, which can be
written as:
Eθ[maxtNB(t,θ)]
and the expected net benefit of strategy that would be
adopted given current (imperfect) information, which
can be presented as:
maxt[EθNB(t,θ)]
The formula can be shown as follows:
EVPI = Eθ[maxtNB(t,θ)] − maxt[EθNB(t,θ)]
where θ is the set of parameters for the model, which
were assigned prior probability distributions; t is the set
of possible decisions or strategies; and NB (t, θ)i st h e
function of net benefit for decision t and parameters θ.
This is presented in terms of THB per patient, and
then to the given population EVPI. The overall EVPI
was multiplied by the proportion of the general popula-
tion aged 18 and projected by the Thai Office of the
National Economic and Social Development Board over
a 5-year period. This was assumed to be the operating
period of the HIV vaccination program in Thailand with
a discounted rate of 3% per annum.
To quantify the value of receiving further information
on the chosen parameters, partial EVPI is the difference
between the expected value of a decision made with per-
fect information about a particular vector of the para-
meters (θ) and the current optimal decision.
With perfect information, θi is the known vector of
the parameters of interest θ; then the expected net ben-
efit of a decision made would now be found by aver-
aging over the uncertainty in θ that remains once we
know θi and then by selecting the optimal treatment
that provides maximum expected net benefit, and can
be written as:
maxt[EθlθtNB(t,θ)]
At this stage, we do not have perfect information on
θi, so the expected value of any decision made with per-
fect information about θi is found by averaging the
uncertain ranges of the parameters θi and can be pre-
sented as:
Eθi[maxtEθlθtNB(t l θ)]
The additional value of collecting perfect information
on a subset θt of uncertain model parameters is there-
fore given by the following equation:
Eθi[maxtEθlθtNB(t l θ)] − maxt[EθlθtNB(t,θ)]
The analysis of partial EVPI requires an explicit state-
ment of the value of the ceiling ratio; therefore, this
analysis applied the Thai WTP threshold at 100,000
THB.
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